November 23, 2022 Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Read More
November 3, 2022 Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
Read More
October 26, 2022 Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
Read More
October 12, 2022 Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
Read More
September 28, 2022 Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update
Read More
August 19, 2022 Ryvu Therapeutics presents its Development Plans for 2022-2024, aims to accelerate its mission
Read More
August 17, 2022 EIB to support Ryvu Therapeutics’ discovery, research and development of new cancer treatments with €22 million
Read More
July 26, 2022 Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board
Read More
July 7, 2022 Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
Read More
June 10, 2022 Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress
Read More
Posts navigation
